Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Regeneron Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$64.39B | 14.7x | 1.33 | US$601.92 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 41.7% Upside | Upgrade to Pro+ | |
Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | US$48.94B | 58x | US$69.47 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.4% Upside | Upgrade to Pro+ | ||
argenx ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | US$36.99B | 43.6x | 0.13 | US$614.76 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.4% Upside | Upgrade to Pro+ | |
BeiGene ADS | NASDAQ | Healthcare | Biotechnology & Medical Research | US$27.66B | -44.4x | -1.4 | US$244.90 | -4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.6% Upside | Upgrade to Pro+ | |
Summit Therapeutics PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | US$27.07B | -59.7x | -1.19 | US$23.47 | -36.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -3.4% Downside | Upgrade to Pro+ | |
IQVIA Holdings | NYSE | Healthcare | Biotechnology & Medical Research | US$26.49B | 19.8x | 6.74 | US$150.28 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 44.2% Upside | Upgrade to Pro+ | |
BioNTech | NASDAQ | Healthcare | Biotechnology & Medical Research | US$24.30B | -31.7x | 0.18 | US$102.02 | -15.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.5% Upside | Upgrade to Pro+ | |
Genmab AS | NASDAQ | Healthcare | Biotechnology & Medical Research | US$12.82B | 11x | 0.12 | US$20.58 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.6% Upside | Upgrade to Pro+ | |
Insmed | NASDAQ | Healthcare | Biotechnology & Medical Research | US$12.63B | -12.5x | 3.35 | US$69.70 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39% Upside | Upgrade to Pro+ | |
WuXi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | US$11.91B | 31.2x | 28.29 | US$2.74 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
WuXi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | US$11.91B | 31.2x | 28.29 | US$2.74 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ICON PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | US$11.70B | 15.1x | 0.49 | US$144.91 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 41.2% Upside | Upgrade to Pro+ | |
Moderna | NASDAQ | Healthcare | Biotechnology & Medical Research | US$10.47B | -3x | -0.11 | US$27.22 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.8% Upside | Upgrade to Pro+ | |
Exelixis | NASDAQ | Healthcare | Biotechnology & Medical Research | US$10.47B | 20.7x | 0.11 | US$37.44 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.8% Upside | Upgrade to Pro+ | |
Ascendis Pharma AS | NASDAQ | Healthcare | Biotechnology & Medical Research | US$9.65B | -22.1x | -0.98 | US$164.15 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.2% Upside | Upgrade to Pro+ | |
Tempus AI | NASDAQ | Healthcare | Biotechnology & Medical Research | US$9.26B | -6.6x | 0.19 | US$52.90 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14% Upside | Upgrade to Pro+ | |
Qiagen | NYSE | Healthcare | Biotechnology & Medical Research | US$9.10B | 107.9x | -1.39 | US$42.07 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.4% Upside | Upgrade to Pro+ | |
Medpace Holdings | NASDAQ | Healthcare | Biotechnology & Medical Research | US$8.56B | 22x | 0.52 | US$298.55 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1.5% Downside | Upgrade to Pro+ | |
EXACT Sciences | NASDAQ | Healthcare | Biotechnology & Medical Research | US$8.44B | -8.1x | 0.02 | US$45.46 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.6% Upside | Upgrade to Pro+ | |
Bio-Techne | NASDAQ | Healthcare | Biotechnology & Medical Research | US$7.93B | 50x | -1.63 | US$50.25 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Revolution Med | NASDAQ | Healthcare | Biotechnology & Medical Research | US$7.21B | -10.9x | -1.57 | US$38.77 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Madrigal Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$7.17B | -14.8x | 1.5 | US$326.79 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.4% Upside | Upgrade to Pro+ | |
Legend Bio | NASDAQ | Healthcare | Biotechnology & Medical Research | US$6.29B | -35.3x | -0.51 | US$34.28 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Telix Pharmaceuticals ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | US$6.18B | 190.5x | 0.22 | US$18.80 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.6% Upside | Upgrade to Pro+ | |
Charles River Laboratories | NYSE | Healthcare | Biotechnology & Medical Research | US$5.64B | 574.8x | -5.17 | US$114.66 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.7% Upside | Upgrade to Pro+ | |
Blueprint Medicines Corp | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.59B | -81.5x | -0.92 | US$87.66 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Verona Pharma ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.50B | -30.5x | 0.14 | US$65.46 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.6% Upside | Upgrade to Pro+ | |
Nuvalent | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.25B | -18.6x | 0.24 | US$73.45 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 48.7% Upside | Upgrade to Pro+ | |
Krystal Biotech | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.88B | 54x | 0.08 | US$167.65 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.3% Upside | Upgrade to Pro+ | |
Cytokinetics Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.78B | -7.7x | -2.31 | US$40.43 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ionis Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.72B | -9.8x | 0.53 | US$29.70 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alkermes Plc | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.58B | 12.4x | 3.45 | US$27.84 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.9% Upside | Upgrade to Pro+ | |
Vaxcyte | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.19B | -8.8x | -1.04 | US$32.92 | -4.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
PureTech Health | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.08B | -56.7x | 0.06 | US$17.26 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Arcellx | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.51B | -32.3x | 0.88 | US$63.74 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Soleno Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.36B | -16.7x | 0.21 | US$73.26 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43.8% Upside | Upgrade to Pro+ | |
Crispr Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.28B | -8.9x | 0.07 | US$38.27 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Akero Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.26B | -11x | 0.4 | US$41 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Scholar Rock | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.09B | -12.5x | 0.58 | US$32.81 | -4.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 45.4% Upside | Upgrade to Pro+ | |
Crinetics Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.02B | -8.8x | US$32.39 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Merus | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.01B | -13x | 1.18 | US$43.53 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Xenon Pharmaceuticals | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.87B | -12.5x | 1.11 | US$37.62 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Viking Therapeutics Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.79B | -21.8x | 2.27 | US$24.99 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Protagonist Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.73B | 10x | 0.03 | US$44.50 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alvotech | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.53B | -11.2x | -0.17 | US$7.94 | -5.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
MoonLake Immunotherapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.50B | -20.6x | 0.13 | US$39.42 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Veracyte Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.50B | 100.1x | 0.77 | US$32.23 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.2% Upside | Upgrade to Pro+ | |
Immunovant | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.48B | -5.6x | 0.15 | US$14.73 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ACADIA | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.45B | 10.8x | 0.02 | US$14.73 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biohaven Pharma | NYSE | Healthcare | Biotechnology & Medical Research | US$2.39B | -3.4x | 0.04 | US$19.84 | -15.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |